You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Novavax’s COVID-19 vaccine ‘highly’ effective against UK variant

Novavax has announced that its COVID-19 vaccine NVX-CoV2373 has a final efficacy of 96.3% against mild, moderate and severe disease caused by the original COVID-19 strain in its UK-based Phase III trial.